Clinical Trial Update: Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids [Phase 1, Phase 2]

View source ↗

Summary

Exploratory Phase 1/2 study evaluating the efficacy and safety of Juvista (250 ng) given after excision of ear-lobe keloids; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keloid

Drugs mentioned

• Juvista 250 ng (recombinant human basic fibroblast growth factor (rh-bFGF))

Snippet

Sponsor: Renovo | Conditions: Keloid | Phase 1, Phase 2 | Status: COMPLETED